cfDNA methylation sequencing: a precision tool for early detection of neurodegenerative disorders
)
- Published on: November 5 2025
Neurodegenerative diseases remain difficult to detect and monitor with high precision. However, emerging sequencing-based methylation tools are enabling new ways to track the progression of these complex conditions.
In this on-demand webinar, speakers from Wasatch BioLabs and the University of Kansas Alzheimer’s Disease Research Center will explore how the analysis of cell-free DNA (cfDNA), powered by Oxford Nanopore Technologies, is advancing the detection and monitoring of neurodegenerative conditions such as Alzheimer’s and Parkinson’s.
Understand how cfDNA methylation profiling using Oxford Nanopore sequencing enables accurate, cell-type–specific identification of neurodegenerative processes from blood
Explore case studies from Wasatch BioLabs demonstrating early detection and differentiation of Alzheimer’s, Parkinson’s, and related disorders
Discover how Oxford Nanopore sequencing technology uniquely supports native methylation detection and multiomic approaches, enabling new methods for precision medicine
